- Jan 18, 2001
- 3,514
- 1,179
- 113
- School/Org
- ODwire
- City
- Lansdale
- State
- PA
SAN JOSE, Calif., October 17, 2025—Lumenis Be. Inc., a leading energy-based medical device company for ophthalmic and aesthetic solutions, has announced the launch of Digital Duet 2.0, the latest evolution of its pioneering digital SLT+YAG platform for glaucoma and posterior capsulotomy treatment. Combining imaging and connectivity with a user-centric experience, this next-generation Digital Duet reflects the company’s longstanding leadership in ophthalmic laser innovation.
Developed by Lumenis, the inventor of SLT, Digital Duet 2.0’s tailored design brings advanced high-resolution imaging to the center of ophthalmic care. An enhanced integrated camera enables live viewing, high-quality image capturing, and video recording, supporting diagnosis, documentation and communication. Practitioners can capture a wide range of pathologies, including angle imagery, monitor progress, and help train the next generation of ophthalmologists—adding new value to patient care and professional development. Adjustable imaging brightness and optimized visualization ensure clarity and precision in every case.
Digital Duet 2.0 combines advanced digital capabilities with Lumenis’s best-in-class SLT+YAG laser technology. The system features the premium optics of Lumenis engineering, a super-Gaussian beam profile, and SmartV titratable on-axis/off-axis illumination, all of which contribute to optimal visualization and energy efficiency.
Digital Duet 2.0 also streamlines the clinical workflow through network-ready connectivity and automated reporting. The platform integrates seamlessly with electronic medical record (EMR/EHR) systems to simplify documentation and ensure secure data exchange. Customizable clinical reports are automatically generated and exported, reducing administrative burden and freeing up staff resources. These capabilities enable consistent data management and collaboration across clinics, hospitals, and vision care networks.
A new doctor-focused design includes a heads-up display (HUD) and a full HD 15.6-inch touchscreen that integrates all imaging, data, and laser controls into a single, intuitive workspace. With optimized anterior and posterior offset, Digital Duet 2.0 provides flexibility for the practitioner and offers a premium experience that complements high-performing ophthalmic practices.
“Digital Duet 2.0 delivers unrivaled performance for SLT+YAG procedures in the industry,” says Dr. Steven Vold, founder and CEO of Vold Vision. “Digital Duet has always delivered best-in-class SLT capability and superb optics, and the new imaging and workflow capabilities take that excellence even further—enabling smooth and easy operation and transforming how we work and engage with patients. It’s a future-ready platform that helps us stay at the forefront of innovation.”
“Digital Duet 2.0 sets a new gold standard in SLT+YAG technology. As the inventor of SLT, Lumenis is continuing to redefine innovation in ophthalmic laser care, bringing advanced imaging and connectivity that enhance clinical decision-making and patient care,” says Itay Mayer, Chief Commercial Officer, Lumenis. “This next-generation platform reflects our vision to shape the future of glaucoma treatment through digital excellence—empowering practitioners and improving outcomes for their patients.”
*Warnings and risks: Digital Duet is intended for use by trained physicians. For all indications, use is contraindicated when media opacities interfere with clear visualization. Selective laser Trabeculoplasty is contraindicated for eyes with neovascular or angle-closure glaucoma; risks include iritis and transient IOP rise. Posterior Capsulotomy is contraindicated for eyes with extensive corneal dystrophy and chronically elevated IOP; risks include IOP rise, rupture of the hyaloid face, retinal damage, and uveitis. Iridotomy is contraindicated for eyes without pupillary block; risks include transient elevation of IOP, hyphemia, and damage to the lens/retina/choroid. For a complete list of contraindications and risks, refer to the operator manuals.
About Lumenis
Lumenis develops life-changing, minimally invasive solutions for the Aesthetic and Vision markets. We create and commercialize innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. Lumenis has successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters.
Developed by Lumenis, the inventor of SLT, Digital Duet 2.0’s tailored design brings advanced high-resolution imaging to the center of ophthalmic care. An enhanced integrated camera enables live viewing, high-quality image capturing, and video recording, supporting diagnosis, documentation and communication. Practitioners can capture a wide range of pathologies, including angle imagery, monitor progress, and help train the next generation of ophthalmologists—adding new value to patient care and professional development. Adjustable imaging brightness and optimized visualization ensure clarity and precision in every case.
Digital Duet 2.0 combines advanced digital capabilities with Lumenis’s best-in-class SLT+YAG laser technology. The system features the premium optics of Lumenis engineering, a super-Gaussian beam profile, and SmartV titratable on-axis/off-axis illumination, all of which contribute to optimal visualization and energy efficiency.
Digital Duet 2.0 also streamlines the clinical workflow through network-ready connectivity and automated reporting. The platform integrates seamlessly with electronic medical record (EMR/EHR) systems to simplify documentation and ensure secure data exchange. Customizable clinical reports are automatically generated and exported, reducing administrative burden and freeing up staff resources. These capabilities enable consistent data management and collaboration across clinics, hospitals, and vision care networks.
A new doctor-focused design includes a heads-up display (HUD) and a full HD 15.6-inch touchscreen that integrates all imaging, data, and laser controls into a single, intuitive workspace. With optimized anterior and posterior offset, Digital Duet 2.0 provides flexibility for the practitioner and offers a premium experience that complements high-performing ophthalmic practices.
“Digital Duet 2.0 delivers unrivaled performance for SLT+YAG procedures in the industry,” says Dr. Steven Vold, founder and CEO of Vold Vision. “Digital Duet has always delivered best-in-class SLT capability and superb optics, and the new imaging and workflow capabilities take that excellence even further—enabling smooth and easy operation and transforming how we work and engage with patients. It’s a future-ready platform that helps us stay at the forefront of innovation.”
“Digital Duet 2.0 sets a new gold standard in SLT+YAG technology. As the inventor of SLT, Lumenis is continuing to redefine innovation in ophthalmic laser care, bringing advanced imaging and connectivity that enhance clinical decision-making and patient care,” says Itay Mayer, Chief Commercial Officer, Lumenis. “This next-generation platform reflects our vision to shape the future of glaucoma treatment through digital excellence—empowering practitioners and improving outcomes for their patients.”
# # #
*Warnings and risks: Digital Duet is intended for use by trained physicians. For all indications, use is contraindicated when media opacities interfere with clear visualization. Selective laser Trabeculoplasty is contraindicated for eyes with neovascular or angle-closure glaucoma; risks include iritis and transient IOP rise. Posterior Capsulotomy is contraindicated for eyes with extensive corneal dystrophy and chronically elevated IOP; risks include IOP rise, rupture of the hyaloid face, retinal damage, and uveitis. Iridotomy is contraindicated for eyes without pupillary block; risks include transient elevation of IOP, hyphemia, and damage to the lens/retina/choroid. For a complete list of contraindications and risks, refer to the operator manuals.
About Lumenis
Lumenis develops life-changing, minimally invasive solutions for the Aesthetic and Vision markets. We create and commercialize innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. Lumenis has successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters.
